🔍

MEDPLUS - Medplus Health

📊 NSE: MEDPLUS 🏢 Trading 📅 Last Updated: 12/14/2025 9:46

📢 Recent Corporate Announcements

MedPlus Receives Stay Orders Against License Suspensions in Pune, Maharashtra

🟢 POSITIVE ⭐ 6/10

REGULATORY 📅 28 Apr 2026, 04:27 PM

MedPlus Health Services Limited has successfully obtained two stay orders from authorities in Pune, Maharashtra, against previously announced license suspensions. These suspensions were initially disclosed in regulatory filings dated February 4, 2026, and March 4, 2026. The stay orders provide immediate relief, allowing the company to maintain its retail operations in the affected region. This development mitigates the risk of revenue loss from potential store closures in the Pune market.

Received 2 stay orders against license suspensions from authorities in Pune, Maharashtra
Follows previous regulatory disclosures made on February 4 and March 4, 2026
Ensures operational continuity for the affected pharmacy outlets in the region
Compliance update filed under Regulation 30 of SEBI (LODR) Regulations, 2015

💡 Investors should view this as a positive development that reduces near-term regulatory friction in a key urban market. Continue to monitor for the final resolution of these regulatory proceedings to ensure long-term compliance stability.

MedPlus Subsidiary Faces 5-Day License Suspension for Bangalore Store; Revenue Impact ₹5.39 Lacs

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 22 Apr 2026, 05:59 PM

MedPlus Health Services' subsidiary, Optival Health Solutions, has received a suspension order for its drug license at a specific store in Jayanagar, Bangalore. The suspension is for a period of five days due to alleged violations of Rule 65 of the Drugs and Cosmetics Act, 1940. The company estimates a potential revenue loss of approximately ₹5.39 lacs during this period. While the financial impact is minimal relative to the company's total revenue, it highlights ongoing regulatory oversight on pharmacy operations.

Drug license of a Jayanagar, Bangalore store suspended for 5 days
Action taken by Assistant Director, Drugs Control Administration, Karnataka
Estimated potential revenue loss of ₹5.39 lacs during the suspension period
Violation cited under Rule 65 of Drugs and Cosmetics Act, 1940 and Rules, 1945

💡 Investors should treat this as a routine regulatory matter with negligible financial impact. Monitor if such suspensions become frequent across other locations, which could indicate systemic compliance issues.

MedPlus Subsidiary Faces Drug License Suspensions in Karnataka; Total Revenue Impact of ₹4.98 Lacs

🔴 NEGATIVE ⭐ 3/10

REGULATORY 📅 17 Apr 2026, 05:40 PM

MedPlus Health Services' subsidiary, Optival Health Solutions, has received suspension orders for drug licenses at two of its retail stores in Bangalore, Karnataka. The Jayanagar store faces a 4-day suspension with an estimated revenue loss of ₹3.68 lacs, while the Srinivasanagar store faces a 5-day suspension with a loss of ₹1.30 lacs. These orders were issued by the Drugs Control Administration for violations under Rule 65 of the Drugs and Cosmetics Act. While the financial impact is negligible relative to the company's total turnover, it highlights localized regulatory compliance risks.

Suspension of drug licenses for two stores in Bangalore for durations of 4 and 5 days.
Total quantifiable revenue loss estimated at approximately ₹4.98 lacs across both locations.
Violations cited under Rule 65 of the Drugs and Cosmetics Act, 1940 and Rules, 1945.
Orders received from the Assistant Director, Drugs Control Administration, Bangalore Circle - 3.

💡 The financial impact is immaterial to the company's consolidated performance, so no immediate portfolio changes are necessary. Investors should however monitor if such regulatory lapses become a recurring pattern across the store network.

MedPlus Subsidiary Faces Drug License Suspensions; Total Revenue Impact ₹6.81 Lacs

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 15 Apr 2026, 05:08 PM

MedPlus Health Services Limited has reported that its subsidiary, Optival Health Solutions Private Limited, received suspension orders for drug licenses at two store locations. The store in Eluru, Andhra Pradesh, faces a 7-day suspension with a potential revenue loss of ₹5.85 lacs. Additionally, a store in Saheednagar, Odisha, faces a 2-day suspension with a potential revenue loss of ₹0.96 lacs. The total financial impact is approximately ₹6.81 lacs, which is considered immaterial relative to the company's overall operations.

7-day drug license suspension for the Eluru, Andhra Pradesh store starting April 2026
2-day drug license suspension for the Saheednagar, Odisha store
Total estimated revenue loss across both locations is ₹6.81 lacs
Actions taken under Rule 65 of the Drugs and Cosmetics Act, 1940
The suspensions are localized to specific stores and do not affect broader operations

💡 No action is required as the financial impact is negligible. Investors should treat this as a routine regulatory disclosure regarding localized compliance issues.

MedPlus Subsidiary Store in Odisha Faces 5-Day License Suspension; ₹3.80 Lakh Revenue Impact

🔴 NEGATIVE ⭐ 3/10

REGULATORY 📅 11 Apr 2026, 12:20 PM

MedPlus Health Services Limited's subsidiary, Optival Health Solutions Private Limited, has received a five-day suspension order for its drug license at a store in Bahadur Bagicha pada, Odisha. The order, issued by the Dy. Drugs Controller, Southern Zone, Berhampur, follows alleged violations of Rule 65 of the Drugs and Cosmetics Act, 1940. The company estimates a potential revenue loss of approximately ₹3.80 lakhs during the suspension period. While the financial impact is negligible on a consolidated basis, it highlights localized regulatory oversight.

Drug license suspended for 5 days at a specific store in Bahadur Bagicha pada, Odisha.
Action taken by the Dy. Drugs Controller, Southern Zone, Berhampur, Odisha.
Violation cited under Rule 65 of the Drugs and Cosmetics Act, 1940 and Rules, 1945.
Estimated financial impact is a revenue loss of approximately ₹3.80 lakhs.

💡 No immediate action is required as the financial impact is immaterial to the company's overall performance. Investors should monitor for any recurring patterns of regulatory non-compliance across other store locations.

MedPlus Subsidiary Store in Telangana Faces Two-Day Drug License Suspension

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 09 Apr 2026, 06:05 PM

MedPlus Health Services Limited has reported that its subsidiary, Optival Health Solutions Private Limited, received a suspension order for a drug license at its Jadcherla, Telangana store. The suspension, issued by the Drugs Control Administration, is effective for a period of two days following the order received on April 8, 2026. The regulatory action was taken due to alleged violations of Rule 65 of the Drugs and Cosmetics Act, 1940. The company has quantified the potential revenue loss at a negligible amount of approximately ₹0.28 lacs.

Two-day suspension of drug license for a store located in Jadcherla, Telangana.
Action initiated by the Assistant Director, Drugs Control Administration, Mahabubnagar.
Alleged violation of Rule 65 of the Drugs and Cosmetics Act, 1940 and Rules, 1945.
Estimated financial impact is a minor revenue loss of ₹0.28 lacs.
Order received by the subsidiary on April 8, 2026.

💡 No immediate action is required as the financial impact is immaterial to the company's overall operations. Investors should only be concerned if such regulatory lapses become a recurring pattern across a larger number of stores.

MedPlus Subsidiary Faces 2-Day License Suspension for Telangana Store; Minimal Financial Impact

🟡 NEUTRAL ⭐ 2/10

REGULATORY 📅 03 Apr 2026, 04:53 PM

MedPlus Health Services Limited has reported that its subsidiary, Optival Health Solutions Private Limited, received a suspension order for a drug license at its Jangaon, Telangana store. The suspension is effective for two days due to alleged violations under Rule 65 of the Drugs and Cosmetics Act, 1940. The company has quantified the potential revenue loss at a negligible ₹0.16 lacs. This appears to be a localized compliance issue with no material impact on the company's consolidated financials.

Drug license for the Station Road Jangaon store in Telangana suspended for a period of 2 days.
Order issued by the Assistant Director, Drugs Control Administration, Warangal, on April 2, 2026.
Estimated financial impact is a potential revenue loss of approximately ₹0.16 lacs.
Action taken due to alleged contravention of Rule 65 of the Drugs and Cosmetics Rules, 1945.

💡 Investors should view this as a minor regulatory event with no significant impact on the company's stock price or long-term fundamentals. No immediate action is required based on this specific disclosure.

MedPlus Subsidiary Faces 3-Day License Suspension for Telangana Store; Revenue Impact ₹0.60 Lacs

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 29 Mar 2026, 05:42 PM

MedPlus Health Services Limited has reported that its subsidiary, Optival Health Solutions Private Limited, received a suspension order for a drug license at a single store in Parkal, Telangana. The suspension, issued by the Drugs Control Administration, Warangal, is effective for three days due to alleged violations of Rule 65 of the Drugs and Cosmetics Act, 1940. The company has quantified the potential revenue loss at a negligible ₹0.60 lacs. This is a localized regulatory matter with minimal impact on the company's overall consolidated operations.

Drug license suspended for a store situated at Parkal Main Road, Telangana for a period of 3 days.
Order issued by the Assistant Director, Drugs Control Administration, Warangal, under Rule 65 of Drugs and Cosmetics Act.
Potential revenue loss estimated at approximately ₹0.60 lacs (₹60,000).
The suspension order was received by the company on March 28, 2026.

💡 Investors should treat this as a routine regulatory update with no material impact on the company's valuation or financial health. No action is required unless such suspensions become a systemic pattern across multiple regions.

MedPlus Shareholders Approve Material Related Party Transactions with 99.99% Majority

🟡 NEUTRAL ⭐ 6/10

REGULATORY 📅 27 Mar 2026, 07:01 PM

MedPlus Health Services Limited has received shareholder approval for material related party transactions with its material subsidiary, Optival Health Solutions Private Limited. The resolution was passed via a postal ballot process with an overwhelming 99.9993% of valid votes in favor. Public institutional investors showed strong support, with 90.52% of their holdings participating and voting entirely in favor of the resolution. This approval ensures the continuation of essential business dealings between the parent company and its primary operational subsidiary.

Resolution for material RPT with subsidiary Optival Health Solutions passed with 99.9993% majority.
Public institutional participation was high at 90.52%, with 100% of those votes (4,69,79,119 shares) in favor.
Only 324 votes were cast against the resolution out of a total of 4,75,64,070 valid votes.
Related party votes totaling 6,09,687 were identified and excluded from the valid vote count as per regulatory requirements.
The voting period concluded on March 26, 2026, with results declared on March 27, 2026.

💡 Investors should view this as a routine but necessary regulatory clearance that ensures operational continuity. The high level of institutional support is a positive indicator of confidence in the company's internal governance.

MedPlus Health Services to Close Trading Window from April 1, 2026, for FY26 Results

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 25 Mar 2026, 03:28 PM

MedPlus Health Services Limited has announced the closure of its trading window for all designated persons effective April 1, 2026. This move is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the company's audited financial results for the quarter and year ending March 31, 2026. The trading window will remain closed until 48 hours after the financial results are officially declared. The specific date for the board meeting to approve these results will be communicated at a later date.

Trading window closure starts from April 1, 2026, for all designated persons.
Closure is related to the audited financial results for the quarter and year ending March 31, 2026.
The window will reopen 48 hours after the declaration of the financial results.
The date for the board meeting to consider the results is yet to be announced.

💡 This is a routine regulatory announcement with no immediate impact on stock fundamentals; investors should watch for the upcoming Q4 and FY26 earnings date.

MedPlus Clarifies Delay in SEBI Regulation 30 Disclosure Filing

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 24 Mar 2026, 05:12 PM

MedPlus Health Services Limited has issued a formal clarification regarding a delay in reporting a material event under Regulation 30 of SEBI (LODR) Regulations. The company missed the mandatory 24-hour disclosure window for an event related to its March 23, 2026, filing, citing an inadvertent oversight. Management has assured the exchanges that corrective measures are being implemented to strengthen internal monitoring systems. While the delay is administrative, it highlights a temporary lapse in the company's compliance framework.

Delayed disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015, cited as inadvertent oversight
The material event intimation was eventually submitted on March 23, 2026
Company confirms no intent to withhold material information from stock exchanges
Corrective measures initiated to strengthen internal reporting and monitoring systems for future compliance

💡 This is a minor administrative matter and does not impact business fundamentals. Investors should focus on the specific material event disclosed on March 23 to evaluate any actual operational impact.

MedPlus Subsidiary Faces 3-Day License Suspension for Karnataka Store; Revenue Impact ₹0.37 Lacs

🟡 NEUTRAL ⭐ 2/10

REGULATORY 📅 23 Mar 2026, 05:48 PM

MedPlus Health Services Limited has reported that its subsidiary, Optival Health Solutions Private Limited, received a suspension order for a drug license at a single store in Mandya, Karnataka. The suspension is effective for three days due to alleged violations under Rule 65 of the Drugs and Cosmetics Act, 1940. The company has quantified the potential revenue loss at a negligible ₹0.37 lacs. This event is localized to one outlet and does not impact the company's overall business operations.

Drug license for the Guthal Road, Mandya store suspended for a duration of 3 days
Action initiated by the Assistant Director, Drugs Control Administration, Mandya Circle
Violation cited under Rule 65 of the Drugs and Cosmetics Act, 1940 and Rules, 1945
Estimated financial impact is a minor revenue loss of approximately ₹0.37 lacs

💡 No immediate action is required as the financial impact is immaterial. Investors should only be concerned if such regulatory suspensions become a recurring pattern across multiple store locations.

MedPlus Subsidiary Faces 7-Day Drug License Suspension at Andhra Pradesh Store

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 21 Mar 2026, 04:56 PM

MedPlus Health Services Limited's subsidiary, Optival Health Solutions Private Limited, has received a suspension order for its drug license at a specific store in Bhimavaram, Andhra Pradesh. The suspension is for a duration of seven days following an order from the Drugs Control Administration. The company has cited violations under Rule 65 of the Drugs and Cosmetics Act, 1940. The financial impact is expected to be minimal, with an estimated revenue loss of approximately ₹1.93 lacs.

Drug license suspended for 7 days at the Bhimavaram P P Road store in Andhra Pradesh.
Order issued by the Assistant Director, Drugs Control Administration, Eluru & West Godavari District.
Estimated potential revenue loss quantified at ₹1.93 lacs.
Violation pertains to Rule 65 of the Drugs and Cosmetics Act, 1940 and Rules, 1945.

💡 No immediate action is required as the financial impact is negligible relative to the company's total revenue. Investors should treat this as a routine regulatory matter unless such suspensions become frequent across multiple locations.

MedPlus Subsidiary Faces 5-Day Drug License Suspension in Karnataka; Revenue Impact ₹1.77 Lakhs

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 17 Mar 2026, 06:27 PM

MedPlus Health Services Limited has reported that its subsidiary, Optival Health Solutions Private Limited, received a suspension order for a drug license at a store in Lingaraj Nagar, Karnataka. The suspension, issued by the Drugs Control Administration of Hubli Circle, is effective for five days following violations under Rule 65 of the Drugs and Cosmetics Act. The company estimates the financial impact to be a potential revenue loss of approximately ₹1.77 lakhs. While the financial impact is minimal, it highlights regulatory oversight on pharmacy operations.

Drug license suspended for 5 days at a store in Lingaraj Nagar, Karnataka
Action taken by Assistant Director, Drugs Control Administration, Hubli Circle
Violation cited under Rule 65 of the Drugs and Cosmetics Act, 1940
Estimated potential revenue loss quantified at ₹1.77 lakhs

💡 This is a minor operational issue affecting a single store with negligible impact on consolidated financials. No immediate action is required, though investors should monitor for any patterns of regulatory non-compliance across the store network.

MedPlus to Incorporate Wholly Owned Subsidiary for CSR Activities

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 16 Mar 2026, 06:55 PM

MedPlus Health Services Limited has announced that its Board of Directors approved the incorporation of a new Wholly Owned Subsidiary (WOS) on March 16, 2026. This entity will be established as a Section 8 company under the Companies Act, 2013, which is a non-profit structure. The primary objective of this subsidiary is to exclusively manage and undertake the company's Corporate Social Responsibility (CSR) activities. MedPlus will maintain 100% control and ownership of the new entity through cash subscription at face value.

Board approved the formation of a Section 8 Wholly Owned Subsidiary on March 16, 2026.
The new entity is dedicated exclusively to undertaking the company's CSR initiatives.
MedPlus Health Services Limited will hold 100% shareholding in the subsidiary.
Subscription to the share capital will be made in cash at face value.

💡 This is a routine administrative and governance-related update with no direct impact on the company's financial performance. Investors should remain focused on the company's core pharmacy retail operations and expansion metrics.

View All MEDPLUS Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Consolidated revenue grew 9.17% in FY 2025 to INR 61,846.69 million. By segment: Retail grew 8.6% to INR 60,268.86 million; Diagnostic services grew 44.3% to INR 1,081.07 million; and Other segments grew 15.4% to INR 10.60 million.

Geographic Revenue Split

The company operates 4,930 stores across 13 states and 1 union territory. In Q2 FY 2026, 68 net store additions were made beyond Tier-One cities, aligning with the strategy to deepen retail healthcare access in underserved markets.

Profitability Margins

Consolidated gross margin increased from 21.92% in FY 2024 to 24.37% in FY 2025, reaching a new high of 26.1% in Q2 FY 2026. This 240 bps YoY improvement is driven by the increasing share of high-margin private label products.

EBITDA Margin

Consolidated operating EBITDA for Q2 FY 2026 stood at 5.3% (INR 887 million). Mature outlets (older than 12 months) maintained a solid 11.8% store-level EBITDA margin, demonstrating strong unit economics upon store maturity.

Capital Expenditure

Not disclosed in absolute INR Cr; however, the company added 145 gross stores in Q2 FY 2026 and maintains a property bank of 400+ locations for future expansion.

⚙️ Operational Drivers

Raw Materials

Branded pharmaceutical products represent approximately 75% of sales. Private label pharmaceuticals and FMCG goods constitute 21.5% of total revenue as of Q2 FY 2026.

Capacity Expansion

Current network includes 4,930 stores covering 2.6 million+ square feet as of Q2 FY 2026. The company added 398 stores in FY 2025 and 117 net stores in Q2 FY 2026.

Raw Material Costs

Cost of goods sold was INR 46,406.61 million in FY 2025, representing 75.03% of total income, down from 77.52% in FY 2024 due to better supply chain efficiency.

Manufacturing Efficiency

The company utilizes a backward-integrated value chain and tech-driven inventory management to maintain cost efficiency across 48k+ SKUs in warehouses.

📈 Strategic Growth

Expected Growth Rate

6.50%

Growth Strategy

Growth will be driven by a cluster-based expansion strategy focusing on deeper penetration in 13 states, a pilot franchisee model, and increasing private label revenue share to 20-25%. The company is also expanding its diagnostics segment, which grew 44.3% in FY 2025.

Products & Services

Branded and private-label medicines, wellness products, FMCG goods, pathology and radiology diagnostic services, and insurance broking.

Brand Portfolio

MedPlus, MedPlus Mart, MedPlus Lens, MedPlus Labs.

New Products/Services

Private label pharma sales reached 12.1% of revenue in Q2 FY 2026, while non-pharma private labels contributed 9.6%.

Market Expansion

Expansion into Tier II and III cities to capitalize on rising health awareness and underserved retail healthcare markets.

Market Share & Ranking

2nd largest pharmacy retailer in India by revenue.

🌍 External Factors

Industry Trends

The Indian retail pharmacy industry is growing rapidly and moving toward consolidation and digital transformation. MedPlus is positioned as a pioneer in the organized retail format with a 19-year presence.

Competitive Landscape

Intense competition from both traditional unorganized retail pharmacies and well-funded online pharmacy platforms.

Competitive Moat

Durable advantages include a backward-integrated supply chain, a massive network of 4,900+ stores, and high customer stickiness (70% retention) through loyalty programs. These are sustainable due to the high capital requirement for competitors to build similar infrastructure.

Macro Economic Sensitivity

Sensitive to India's growing chronic disease burden and increasing internet penetration which drives ePharmacy (omnichannel) demand.

Consumer Behavior

Shift toward impulsive buying in the non-pharma/FMCG segment, where there is no doctor-prescribed dosage limit, driving higher basket values.

⚖️ Regulatory & Governance

Industry Regulations

Operations are heavily influenced by the Drug Pricing Control Order (DPCO) and compliance with various pharmaceutical retail and diagnostic licensing laws.

Legal Contingencies

No material changes, commitments, or insolvency proceedings were initiated during the financial year ended March 31, 2025.

⚠️ Risk Analysis

Key Uncertainties

Promoter share pledging is identified as a financial risk that affects investor confidence. Pharmacist attrition is an HR risk that could impact service quality.